Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model.
Diana Rose E RanoaPreeti SharmaClaire P SchaneAmber N LewisEdward ValdezVenkata V V R MaradaMarlies V HagerWill MontgomerySteven P WolfKarin SchreiberHans SchreiberKeith BaileyTimothy M FanPaul J HergenrotherEdward J RoyDavid M KranzPublished in: Journal for immunotherapy of cancer (2023)
The findings support the development of affinity-optimized CAR-T cells as a potential treatment for established ovarian cancer, with the most effective CARs mediating a distinct pattern of inflammatory cytokine release in vitro. Importantly, the most potent Tn-dependent CAR-T cells showed no evidence of toxicity in tumor-bearing mice in a syngeneic, immunocompetent system.